Companies › NAMS

Newamsterdam Pharma Co NV (NAMS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001936258 · EDGAR filings · Updated 2026-07-24

Newamsterdam Pharma Co NV (NAMS) has reported institutional ownership of 105.1%, with 168 institutional managers holding positions valued at $3.94B per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02).

Filings this week (3)

• 2026-07-24 — Current report (8-K) filed
• 2026-07-22 — Current report (8-K) filed
• 2026-07-22 — Insider transaction reported (Form 4)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-06-24 — Insider transaction reported (Form 4)
• 2026-06-05 — Employee-plan registration (S-8) filed
• 2026-06-04 — SCHEDULE 13G/A filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Newamsterdam Pharma Co NV has 168 institutional holders and institutional ownership of 105.1%.

Insider activity

Insiders reported 96 transactions (6 buys, 49 sells) across 13 reporting insiders, with a net reported value of −$62.6M.

Data flags from SEC filings

Related companies

IRHYTHM HOLDINGS INC (IRTC) · SPYRE THERAPEUTICS INC (SYRE) · LIGAND PHARMACEUTICALS INC (LGND) · SOTERA HEALTH CO (SHC) · INDIVIOR PHARMACEUTICALS INC (INDV) · TANGO THERAPEUTICS INC (TNGX)